

RECEIVED

MAR 31 2003

TECH CENTER 1600/2900



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Box RCE, Commissioner for Patents, Washington, D.C. 20231, on the date shown below.

Dated: March 21, 2003

Signature: *[Signature]*
(Harvey L. Cohen)

Docket No.: EGYP 3.0-008
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of :
Cesaro et al :
Application No.: 09/653,717 : Group Art Unit: 1614
Filed: September 1, 2000 : Examiner: R. Cook
For: USE OF NICOTINE OR DERIVATIVE :
THEREOF FOR THE TREATMENT OF :
NEUROLOGIC DISEASES, IN :
PARTICULAR, PARKINSON DISEASE X

Box RCE
Commissioner for Patents
Washington, DC 20231

AMENDMENT

Dear Sir:

In response to the official action mailed October 22, 2002, applicant submits the following amendments and remarks. Applicants' Request for Continued Examination is also enclosed.

IN THE CLAIMS

Insert new claims 45 and 46, as follows:


Rule 126
56 45. (NEW) A method for improving the functionality of D1 and D2 dopaminergic receptors associated with neurodegenerative diseases, multi-systemic atrophy, or both, in a human mammal comprising administering over a long term period an effective dose of at least two drug components comprising as a first component nicotine or a nicotine derivative, and a second component comprising L-DOPA in a dose at least 30% lower than the effective dose when L-DOPA is administered in the absence of said first component and a dopaminergic agonist.
NO!

D'cont

57. (NEW) A method for treating a neurodegenerative disease, a multi-systemic atrophy, or both, in a human mammal comprising administering over a long term period an effective dose of at least two drug components comprising as a first component, nicotine or a nicotine derivative, and a second component comprising L-DOPA in a dose at least 30% lower than the effective dose when L-DOPA is administered in the absence of said first component and a dopaminergic agonist.



MAR 26 2003

AMENDMENT TRANSMITTAL LETTER				Expedited Procedure	
Application No. 09/653,717	Filing Date September 1, 2000	Examiner R. Cook	Group Art Unit 1614		
Applicant(s): Pierre Cesaro and Gabriel Villafane				Docket No. EGYP 3.0-008	
Invention: USE OF NICOTINE OR DERIVATIVE THEREOF FOR THE TREATMENT OF NEUROLOGIC DISEASES, IN PARTICULAR, PARKINSON DISEASE					
TO THE COMMISSIONER FOR PATENTS					
Transmitted herewith is an amendment in the above-identified application.					
The fee has been calculated and is transmitted as shown below.					
CLAIMS AS AMENDED					
Total Claims	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate	
Total Claims	43	- 51 =	0	x	
Independent Claims	5	- 5 =	0	x	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					
Other fee (please specify):					
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:					0.00
<input checked="" type="checkbox"/> Large Entity	<input type="checkbox"/> Small Entity				
<input checked="" type="checkbox"/> No additional fee is required for this amendment.					
<input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ A duplicate copy of this sheet is enclosed.					
<input type="checkbox"/> A check in the amount of \$ _____ to cover the filing fee is enclosed.					
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge and credit Deposit Account No. 12-1095 as described below. A duplicate copy of this sheet is enclosed.					
<input checked="" type="checkbox"/> Credit any overpayment.					
<input checked="" type="checkbox"/> Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17.					
 Harvey L. Cohen Attorney Reg. No. 28,365					
Dated: March 21, 2003					
LERNER, DAVID, LITTENBERG, KRUMHOLZ & MENTLIK, LLP 600 South Avenue, West Westfield, New Jersey 07090 (908) 518-6425					
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Box RCE, Commissioner for Patents, Washington, DC 20231, on the date shown below.					
Dated: March 21, 2003 Signature:  (Harvey L. Cohen)					